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ORIGINAL PAPER
Pelvic lymph node dissection in prostate cancer staging: evaluation of
morbidity and oncological outcomes
Andries Van Huelea, Filip Poelaerta , Valerie Fonteyneb, Karel Decaesteckera , Piet Ostb and
Nicolaas Lumena
aDepartment of Urology, Ghent University Hospital, Ghent, Belgium; bDepartment of Radiation Oncology, Ghent University
Hospital, Ghent, Belgium
ABSTRACT
Background: To evaluate the morbidity of different surgical approaches for pelvic lymph
node dissection (PLND), to evaluate the influence of morbidity on radiotherapy (RT) planning
and to evaluate a possible therapeutic effect of a more extensive yield of PLND.
Methods: From 2000–2016, 228 patients received staging PLND before primary RT in a single
tertiary care center. Nine patients were excluded for the evaluation of morbidity. Fifty
patients were operated in an open approach, 96 laparoscopic and 73 robot-assisted (RA).
Clavien–Dindo classification was used for evaluating complications. Predictors of biochemical
recurrence (BCR), clinical relapse (CR), cancer-specific survival (CSS) and overall survival (OS)
were evaluated by regression analyses to determine a possible therapeutic effect.
Results: Minimal invasive surgery (laparoscopic or RA) caused five times less major complica-
tions (22% vs. 4.3%, p¼ .001) and a median 3 days shorter hospital stay (5 days versus 2
days, p< .001). Major complications resulted in a delayed (23 days, p< .001) RT start but no
oncological effect was seen. Independent oncological predictors were the number of positive
nodes (BCR, CR, CSS, OS), a lower age (CR), a higher level of initial prostate-specific antigen
(PSA) (BCR) and post-RT PSA (BCR).
Conclusion: Minimal invasive surgery can diminish major complications which delay RT start.
Nodal staging proved to be of importance for prognosis but no therapeutic effect was seen
of performing PLND as such.
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Introduction
Pelvic lymph node dissection (PLND) is the most
reliable way to determine whether there is pelvic
lymph node invasion in prostate cancer (PCa) or
not. Information about the number of positive
lymph nodes, extent of positivity in the nodes and
extranodal extension can be obtained which are
important for prognosis and treatment choice. It
can be performed during radical prostatectomy
(RP) or before primary radiotherapy (RT); this in an
open, laparoscopic or robot-assisted (RA) way.
Performing PLND for staging purposes is indi-
cated if the risk of lymph node invasion is
increased [1,2]. The risk can be predicted by differ-
ent formulas and models. Examples are the Roach
formula and the Memorial Sloan Kettering nomo-
gram [3,4]. Performing PLND, however, has an
impact on morbidity. Postoperative complication
rate varies from 2% to 51% [1]. Complications
include symptomatic lymphoceles, lymphedema of
lower extremities, thrombosis, embolism and ileus.
The total number of lymphoceles – mostly
asymptomatic – is 27% to 61% [5]. Symptomatic
lymphoceles occur in 0% to 8% of patients [6].
Unintended delay of primary treatment could affect
survival outcomes.
Besides staging purposes, some studies suggest
that there is also a therapeutic effect of a more
extensive yield of PLND, observed by less biochem-
ical recurrence (BCR) and a higher cancer-specific
survival (CSS). Other studies contradict these find-
ings [7–10].
The objectives of this research are to evaluate
the morbidity regarding different surgical
approaches of PLND, to evaluate the influence of
morbidity on radiotherapy planning and to evalu-
ate a possible therapeutic effect of a more exten-
sive yield of PLND.
Materials and methods
From January 2000 till September 2016, 228
patients received staging PLND before primary RT
in a single tertiary care center. Approval by the
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local ethics committee was given for this retro-
spective research (EC2015/0959). Six patients had a
conversion, three patients had insufficient informa-
tion on procedure and were therefore excluded
for evaluation of the morbidity related to surgical
procedure (n¼ 219) but included for evaluating
oncological outcomes. Variables included were
patient and tumor characteristics, surgery parame-
ters, hospital stay, complications, adjuvant treat-
ments and follow-up.
PLND was performed when the risk of nodal
involvement was increased (>15% according to
the Roach formula: 2/3prostate-specific antigen
[PSA]þ [Gleason score  6] 10) [3]. Fifty patients
were operated in an open approach, 96 laparo-
scopic and 73 RA. Minimal invasive (MI) PLND (lap-
aroscopic or RA) was performed transperitoneally.
Open PLND was performed extraperitoneally.
Limited PLND was defined as the removal of lymph
nodes of only the obturator fossa or the obturator
fossa and laterally of the internal iliac artery
(n¼ 44). The borders of the extended PLND were
the ureter cranially, pubis or circumflex vein caud-
ally, umbilical ligament medially, genitofemoral
nerve laterally and internal iliac artery medially
(n¼ 174). Ten cases deviated from the templates
and were labelled as missing for this variable.
Clavien-Dindo classification was used for evaluat-
ing complications within 30 days and between 31
and 90 days. Only complications within 30 days
were included for evaluating impact on RT plan-
ning. Biochemical recurrence was defined as PSA
nadirþ2ng/ml. Clinical relapse (CR) was defined as
positive biopsy or imaging for local relapse or
metastases. PSA post-RT was measured on the last
day of radiotherapy.
Statistical analysis was performed using SPSS23
(IBM, NY). Data collection was terminated in
October 2016. Statistical significance was defined
as a p-value <.05. Testing was performed two-
sided. Next to descriptive statistics, comparative
statistics were performed using available hypoth-
esis tests. For comparing two groups, the
Mann–Whitney U-test was used for continuous
nonparametric values. For categorical variables, the
chi-square test or Fisher’s exact-test was used.
Kaplan–Meier and log-rank statistics were used for
estimating survival (BCR, CR, CSS and overall sur-
vival (OS)). Cox regression analyses were used for
calculating hazard ratios. Predictors of BCR, CR, CSS
and OS were evaluated for determining a possible
therapeutic effect of PLND.
Results
Patient and tumor characteristics
Median age was not different between the open
(68 years, interquartile range [IQR] 64–74) and the
MI group (72 years, IQR 65–76) (p¼ .110). In-group
differences were present (RA versus laparoscopic:
p¼ .022, RA versus open: p¼ .012). Other patient
characteristics did not differ (Table 1). Without sig-
nificant differences, 18.8% had intermediate-risk
PCa, 57.8% had high-risk localized PCa and 23.4%
had very high-risk (locally advanced) PCa.
Pathological pN1-stage was more frequent in the
open group compared to the MI group (44.0% vs.
28.4%, p¼ .038) without differences between the
laparoscopic and RA group (p¼ .261). Median
follow-up was longer in the open (85 months,
IQR 50.25–99.50) compared to the laparoscopic
group (56.50 months, IQR 44.25–70.50) (p¼ .001).
Table 1. Patient and tumor characteristics.
Total (n¼ 219) Open (n¼ 50) Laparoscopic (n¼ 96) Robot (n¼ 73) p value
Age at PLND, years (IQR) 70 (64–75) 68 (64–74) 69.5 (63–75) 73 (67–77) .020
BMI, kg/m2 (IQR)a 26.7 (24.4–29.6) 27.1 (25.3–29.4) 26.7 (24.5–30.1) 25.6 (24.0–29.5) .454
iPSA, ng/ml (IQR)b 16 (9.3–27.5) 14.3 (9.3–38.3) 17.4 (10.5–23.0) 15.5 (8.7–28.6) .896
Prostate volume, ml (IQR)c 41 (30–59) 41 (27–59) 38 (29–53) 45 (31–62) .396
cT-stage, n (%) .192
T1-2 109 (49.8) 27 (54.0) 52 (54.2) 30 (41.1)
T3-4 110 (50.2) 23 (46.0) 44 (45.8) 43 (58.9)
Risk group classificationb .317
Intermediate 41 (18.8) 9 (18.0) 21 (21.9) 11 (15.3)
High 126 (57.8) 27 (54.0) 59 (61.5) 40 (55.6)
Very high (locally advanced) 51 (23.4) 14 (28.0) 16 (16.7) 21 (29.2)
cN1, n (%)d 31 (14.8) 7 (14.9) 14 (15.1) 10 (14.3) .990
cM1, n (%)e 4 (2.0) 1 (2.2) 1 (1.1) 2 (3.2) .816
Grade group, n (%)b .226
1 16 (7.3) 3 (6.0) 11 (11.5) 2 (2.8)
2 43 (19.7) 11 (22.0) 21 (21.9) 11 (15.3)
3 35 (16.1) 6 (12.0) 17 (17.7) 12 (16.7)
4 45 (20.6) 12 (24.0) 13 (13.5) 20 (27.8)
5 79 (36.2) 18 (36.0) 34 (35.4) 27 (37.5)
a23 missings, b1 missing, c60 missings, d9 missings e18 missings.
BMI: body mass index; cTNM: clinical tumor/node/metastasis; iPSA: initial prostate specific antigen; IQR: interquartile range; PLND: pelvic
lymph node dissection.
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Follow-up in the laparoscopic group was longer
compared to the RA group (21 months, IQR
9.50–33) (p< .001).
Surgical and postoperative characteristics
There was a correlation comparing template and
surgical method. In the open group, 31.1%
received an extended template compared to 93.9%
in the MI group (p< .001).
Median amount of lymph nodes removed was
higher in the MI group (15 nodes, IQR 11.75–21)
compared to the open group (11.5 nodes, IQR
9–16) (p< .001). When analyzing laparoscopic ver-
sus RA only including the extended template
(n¼ 154), more nodes (14, IQR 11–20 versus 18.5,
IQR 13.25–22) were removed in the RA group
(p¼ .007). The open group only had a median of
13 nodes (IQR 11–18.50) removed in the extended
group (n¼ 14). Operating time was longer in the
MI group (130min, IQR 110–167) compared to
open surgery (102min, IQR 85–130) (p< .001) with-
out differences between laparoscopic and RA
(p¼ .203). There was a higher hemoglobin (Hb)
decrease in the open (1.63g/dl ±1.04) compared
to the MI group (1.19 g/dl ±0.90) (p¼ .031) with-
out differences between laparoscopic and RA
(p¼ .076). There was 30ml less blood loss in the
RA group compared to the laparoscopic
group (p¼ .015).
Duration of hospital stay was shorter in the MI
group (2 days, IQR 2–4) compared with open sur-
gery (5 days, IQR 4–6) (p< .001). There was no dif-
ference comparing the RA approach with the
laparoscopic approach (p¼ .178).
Nine (22.0%) grade III–IV complications occurred
within 30 days in the open group compared to
seven (4.3%) in the MI group (p¼ .001, Table 2).
Five (12.2%) patients had grade IIIa complications
in the open group compared to four (2.5%) in the
MI group (p¼ .018). Only one patient – in the open
group – was found with a IVa complication (pul-
monary embolism, Table 3).
Amount of percutaneous lymphocele drainages
within 30 days was higher in the open group with
five (12.2%) cases compared to the laparoscopic
approach with three (3.4%) cases or the RA group
with one case (1.4%) (open vs. MI: p¼ .018). Other
major complications did not differ apart from the
need for two JJ-stents both in the open group
(open vs. MI: p¼ .040). There were also differences
in the number of patients with scrotal edema (0%
open, 11.2% laparoscopic and 17.8% RA) (p¼ .016).
Radiotherapy planning
Median interval from PLND to start RT (n¼ 219)
was 52 days (IQR 44–64, Figure 1). Median interval
between PLND and start of androgen deprivation
therapy (n¼ 95) was 16 days (IQR 10–37).
When comparing RT intervals based on compli-
cation groups, there was no difference in interval
between the grade 0 (n¼ 110) and grade I–II
group (n¼ 76). When combining these two groups
and comparing it with the grade III–IV group
(n¼ 16), there was a longer interval in the grade
III-IV group (p< .001). Median intervals were 52
days (IQR 44–63) (grade 0-I-II) and 74.5 days (IQR
56.5–119.5) (grade III–IV). When comparing RT
intervals based on surgical method, there was a
longer interval between PLND and start of RT in
the open group (58 days, IQR 48–70) versus the MI
group (52 days, IQR 44–62.25) (p¼ .011). No differ-
ences (p¼ .263) were found comparing laparo-
scopic with RA surgery.
Table 2. Operative and postoperative characteristics.
Total (n¼ 219) Open (n¼ 50) Laparoscopic (n¼ 96) Robot (n¼ 73) p value
Operation time, min (IQR)a 130 (100–160) 102 (85–130) 135 (120–166.50) 130 (102–168) <.001
LN yield (IQR)a 14 (11–20) 11.5 (9–16) 13 (11–19.50) 18 (13–22) <.001
pN1, n (%) 70 (32.0) 22 (44.0) 24 (25.0) 24 (32.9) .064
Extranodal extension, n (%)b 37 (17.3) 10 (21.3) 12 (12.6) 15 (20.8) .273
Hospital stay, days (IQR) 3 (2–4) 5 (4–6) 2 (1–3) 3 (2–4) <.001
Difference in HB, G/DL (SD)c 1,28 (0.94) 1,63 (1.04) 1,30 (0.90) 0,96 (0.88) .022
Extended template, n (%) 168 (80.4) 14 (31.1) 82 (89.1) 72 (100.0) <.001
Clavien–Dindo 0–30 d, n (%)d .004
0 111 (54.7) 19 (46.3) 53 (59.6) 39 (53.4) .359
I–II 76 (37.4) 13 (31.7) 31 (34.8) 32 (43.8) .348
III–IV 16 (7.9) 9 (22.0) 5 (5.6) 2 (2.7) .001
Clavien–Dindo 31–90 d, n (%)b .455
0 173 (80.8) 40 (80.0) 77 (82.8) 56 (78.9) .807
I–II 37 (17.3) 10 (20.0) 15 (16.1) 12 (16.9) .839
III–IV 4 (1.9) 0 (0.0) 1 (1.1) 3 (4.2) .183
Follow-up, months (IQR) 46 (26–72.25) 85 (50.25–99.50) 56.5 (44.25–70.50) 21 (9.50–33) <.001
a3 missings, b5 missings, c88 missings, d16 missings.
Hb: hemoglobin; IQR: interquartile range; Ln: lymph node; pN1: pathology node positive; SD: standard deviation.
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Oncological outcome
Estimated five-year free survival of BCR, CR, CSS
and OS was respectively 83.0% (±3.4), 85.3% (±3.3),
97.1% (±1.4) and 91.5% (±2.2) (Figure 2).
Predictive univariate variables were a lower age
(BCR and CR), higher iPSA (BCR and CR), more
advanced T-stage (BCR and CR), greater number of
positive nodes (BCR, CR, CSS, OS), higher PSA after
RT (BCR and CR) and extranodal extension (BCR).
After multivariable analysis, initial PSA, number of
positive nodes and PSA post-RT were significant
predictors for BCR, and age and number of positive
nodes for CR (Table 4). The number of positive
nodes was the only prognostic factor for CSS
(hazard ratio 1.393 [95% confidence interval
1.145–1.695], p¼ .001) and OS (hazard ratio 1.233
[95% confidence interval 1.071–1.420], p¼ .004).
Discussion
Most studies on PLND in PCa deal on the effect of
different templates on postoperative and onco-
logical outcomes. In this study, focus lies on
the indirect effect of the surgical approach
on outcome.
Lymph node yield was different in all groups
with the largest yield in the RA group followed by
respectively the laparoscopic group and the open
group. Most articles describe a higher or compar-
able yield in open surgery compared to MI
[6,11,12]. Different template use is the most logical
Table 3. List of early postoperative complications (0–30 d) according to Clavien–Dindo.
0–30 d, n (%) Total (n¼ 203) Open (n¼ 41) Laparoscopic (n¼ 83) Robot (n¼ 79) p value
Grade I
Wound dehiscence 3 (1.5) 2 (4.9) 0 (0.0) 1 (1.4) .097
Wound leakage 7 (3.4) 2 (4.9) 3 (3.4) 2 (2.7) .886
Wound granulation 1 (0.5) 1 (2.4) 0 (0.0) 0 (0.0) .202
Transient penile/scrotal edema 23 (11.3) 0 (0.0) 10 (11.2) 13 (17.8) .016
Prolonged lymphorhee 14 (6.9) 3 (7.3) 6 (6.7) 5 (6.8) .993
Lymphedema legs 7 (3.4) 2 (4.9) 2 (2.2) 3 (4.1) .686
Abdominal pain 16 (7.9) 3 (7.3) 5 (5.6) 8 (11.0) .450
Hematoma 3 (1.5) 1 (2.4) 0 (0.0) 2 (2.7) .311
Urinary retention 10 (4.9) 2 (4.9) 3 (3.4) 5 (6.8) .653
Hematuria 3 (1.5) 0 (0.0) 3 (3.4) 0 (0.0) .232
Wound seroma 2 (1.0) 1 (2.4) 1 (1.1) 0 (0.0) .683
Obturator damage 8 (3.9) 1 (2.4) 4 (4.5) 3 (4.1) .907
Grade II
Endocarditis 1 (0.5) 0 (0.0) 0 (0.0) 1 (1.4) .562
Wound infection 1 (0.5) 0 (0.0) 1 (1.1) 0 (0.0) 1.000
Infected lymphocele 2 (1.0) 0 (0.0) 1 (1.1) 1 (1.4) 1.000
Urinary tract infection 10 (4.9) 0 (0.0) 5 (5.6) 5 (6.8) .311
Infected hematoma 1 (0.5) 1 (2.4) 0 (0.0) 0 (0.0) .202
Grade III
Percutaneous drainage lymphocele 9 (4.4) 5 (12.2) 3 (3.4) 1 (1.4) .022
Marsupialization lymphocele 1 (0.5) 0 (0.0) 1 (1.1) 0 (0.0) 1.000
Bowel herniation 1 (0.5) 0 (0.0) 1 (1.1) 0 (0.0) 1.000
Bowel perforation 2 (1.0) 1 (2.4) 0 (0.0) 1 (1.4) 0.505
JJ-Stent (Hydronephrosis) 2 (1.0) 2 (4.9) 0 (0.0) 0 (0.0) 0.040
Grade IV
Pulmonary embolism (life-threatening) 1 (0.5) 1 (2.4) 0 (0.0) 0 (0.0) 0.202
Column total differs from the total amount of patients due to multiple complications possible per patient.
Figure 1. Time to start of radiotherapy according to early postoperative complications (0–30d).
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explanation of these differences [13]. However,
when only the extended template was selected,
more nodes were removed in the RA group com-
pared to the laparoscopic group. The restrictions
of laparoscopic surgery, for example, two-dimen-
sional visualization, counter-intuitive movements
and rigid instruments/lack of movement could be
the reason for the smaller node yield, thus resolved
by the RA approach. The endo-wrist movement
also allows better dissection behind the bifurcation
of the common iliac vessels.
Operation time was approximately half an hour
longer in the MI group. Reasons for this prolonged
duration could be the associated template usage
(extended template has a longer operation time in
this study and other literature), the MI procedure
itself takes longer to perform or the robot docking
time interferes. Eden et al. describes the learning
curve of PLND in a laparoscopic setting [14]. There
was no time difference comparing the laparoscopic
and RA approach. There was more Hb level
decrease in the open group compared to the MI
group. The inherent nature of the procedure can
be responsible. The pneumoperitoneum in laparos-
copy could have a hemostatic function, explaining
this difference. Although there were too few cases
with quantification of blood loss in the open
group, there was less blood loss seen in the RA
group compared to the laparoscopic group with-
out differences in the need for blood transfusions
or Hb changes. Hospital stay was shorter in the
MI group which is an advantage regarding the
economic aspect.
Overall, half of the patients had – mostly minor
– complications within 30 days. A low threshold
for reporting grade I complications was applied
because PLND nowadays remains a staging-pro-
cedure. Suggestions to prevent complications after
PLND are: no dissection lateral to the external iliac
artery, use small clips to close lymphatic ends, use
drains bilaterally, wait to remove the drains after a
volume <50ml/d, inject low molecular weight
heparin in the upper arm [15].
Approximately five times more major complica-
tions were reported in the open group compared
to the MI group. When evaluating all complications
Figure 2. Kaplan–Meier survival plot for biochemical recurrence (BCR) and cancer-specific survival (CSS).
Table 4. Multivariable Cox regression analysis.
BCR p value CR p value
Age / / 0.911 (0.863–0.961) .001
iPSA 1.010 (1.003–1.016) .002 / /
Number of positive nodes 1.278 (1.064–1.535) .009 1.302 (1.120–1.515) .001
PSA post RT 1.027 (1.001–1.054) .041 / /
BCR: biochemical recurrence; CR: clinical relapse; (i) PSA: (initial) prostate-specific antigen; RT: radiotherapy.
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apart, percutaneous lymphocele drainage was
needed approximately five times more in the open
group within 30 days which means major lympho-
cele-related morbidity was diminished by perform-
ing MI PLND. According to Danuser et al.,
transperitoneal (RA RPþ PLND) compared to
extraperitoneal (open RPþ PLND) approach tends
to result in less symptomatic lymphoceles (1 vs.
5%) [16]. This could explain the morbidity-related
advantage of MI. One patient in the open group
had a life-threatening pulmonary embolism. No
life-threatening complications were found in the
MI group. Complications between day 31–90 pre-
sented in 20–30%. This percentage corresponds
with literature findings [1]. Patients operated in a
RA approach were older than patients in the open
group. Men of older age can be seen as more fra-
gile and have besides general comorbidities more
treatment-related comorbidities [17]. Because there
were fewer major complications in the MI group,
this older age only strengthens this result. There
was a correlation comparing the template and the
surgical method. Extended compared to limited
template results in more complications [5].
Because there were more limited templates in the
open surgical group, this also strengthens the con-
clusion on morbidity.
Radiotherapy start was delayed when major
complications occurred and when open surgery
was performed. Open surgery was associated with
more major complications in this study.
Diminishing major complications by MI surgery will
result in less postponed RT planning. No onco-
logical consequences were seen in this study of a
delayed RT start; however, unintended delay of pri-
mary treatment in intermediate- or high-risk PCa
could possibly affect survival outcomes. A study by
Nguyen et al. found a worse time to PSA failure in
localized high-risk PCa when RT treatment was
delayed (cutoff 2.5 months) [18]. Another study
indicated a possible favorable effect on OS when
there was a longer time between PLND and start
of whole pelvis RT in pN1 PCa [19].
The number of positive lymph nodes was associ-
ated with worse survival (BCR, CR, CSS and OS) on
multivariable analysis, highlighting the importance
of good nodal staging. Briganti et al. noted a worse
CSS when a cutoff of two positive nodes was used
[20]. Other negative predictive variables were a
lower age, higher initial PSA and PSA post-RT. No
effect of lymph node yield was seen on oncological
outcomes. Murphy et al. did not find any benefit in
the number of nodes removed on BCR-free survival
in high-risk patients treated with RPþ PLND [10].
DiMarco et al. also did not find any impact on sur-
vival of lymph node extent in N0 PCa treated with
RP [21]. Masterson et al. found a lower BCR risk in
patients with pN0 who had a larger node yield in
clinically localized PCa (þRP) [8]. The lack of pro-
spective studies, conflicting results in retrospective
studies and the Will Rogers phenomenon are
obstacles for making conclusions. Association of
the lymph node yield and the number of positive
nodes found could be of importance [19].
There are limitations in this study. Reporting
bias is the most plausible explanation regarding
differences in scrotal edema. Next to the possible
retrospective reporting bias in the open group,
part of the MI group was followed in a prospective
manner as we implemented a prospective compli-
cation registry. Prospective follow-up tends to
reveal more complications [22]. Because of time
dependency of the approaches, influences of dif-
ferent surgeons and pathologists should be taken
into account regarding node yield. The pN1-status
was higher in the open group compared to the
laparoscopic group. Some open operations were
initially planned to be RPþ PLND (RP was mainly
done in an open approach until recently), but
more invasive tumors (n¼ 1 in the pN1 group) – in
contrary to their clinical staging – or positive nodes
(n¼ 5 in the pN1 group) were found preoperative,
and therefore, a switch was made to only PLND
with primary RT afterwards.
Conclusions
MI surgery – with emphasis on RA surgery –
showed its importance regarding (post)operative
outcomes, especially the lower amount of major
complications. These major complications resulted
in postponed RT start. MI surgery could result in an
earlier start of RT. Level of evidence of this study
regarding therapeutic effect is too low for making
conclusions. However, nodal staging proved to be
of importance for prognosis.
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